Drug Trial Radar · NCT06370715
A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
153
Actual
Start
Apr 18, 2024
Primary completion
Sep 2, 2025
Study completion Sep 2, 2025
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- Cipla Ltd.
- First posted
- Apr 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India. The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).
Conditions
- Diabetes Mellitus, Type 2
Interventions
Insulin Lispro-aabcDrug
Administered subcutaneously
Insulin GlargineDrug
Administered subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <54 Milligrams Per Deciliter (mg/dL)Time frame: Baseline through Week 26
- Rate of Documented Hypoglycemia With Blood Glucose <54 mg/dLTime frame: Baseline through Week 26
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Osmania Medical College & Hospital
Hyderabad, Andhra Pradesh, India
King George Hospital, Visakhapatnam
Visakhapatnam, Andhra Pradesh, India
Diabetes Research Centre
Royapuram, Chennai India, India
Vijyaratna Dibetes Diagnosis Treatment Centre
Ahmedabad, Gujrat, India
Center for Diabetes and Endocrine Care
Bengaluru, Karnataka, India
Sahyadri Super Speciality Hospital
Pune, Maharashtra, India
Chellaram Diabetes Institute
Pune, Maharashtra, India
S. P. Medical College & A G Hospital
Bikaner, Rajasthan, India
Rajasthan University of Health Sciences
Jaipur, Rajasthan, India
Kovai Diabetes Speciality Center and Hospital
Coimbatore, Tamil Nadu, India
Brij Medical Center Pvt. Ltd.
Kanpur, Uttar Pradesh, India
Medical College & Hospital, Kolkata
Kolkata, West Bengal, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.